Innovarus is a pioneering healthcare start-up founded with a singular purpose: to develop innovative treatment solutions that dramatically improve the lives of patients living with chronic and rare diseases.
Every decision we make is guided by the patients who depend on our innovations for a better quality of life.
We apply the highest standards of pharmaceutical science to ensure safety, efficacy, and reliability in every formulation.
We dedicate our expertise to conditions with high unmet medical need, where innovation can have the greatest impact.
We partner with academic institutions, clinicians, and industry leaders to accelerate the path from discovery to patient.
At Innovarus, we develop long-acting injectable treatments that extend the time between doses from days to months. Our approach reduces the burden on patients and healthcare systems, while maintaining consistent therapeutic benefit.
Our treatments are designed to provide sustained therapeutic effect over months, reducing the burden of frequent dosing for patients and healthcare providers.
We target conditions with significant unmet medical need, where long-acting solutions can transform patient outcomes and quality of life.
Our formulations are administered by simple injection — no surgery, no implant removal — making treatment accessible and straightforward.
Our formulations are fully biodegradable and naturally absorbed by the body after the treatment period, leaving nothing behind.
Patients with chronic and rare diseases often face the challenge of frequent injections or daily medication. Our long-acting treatments extend dosing intervals from days to months — reducing hospital visits, improving adherence, and giving patients more freedom in their daily lives.
Our long acting platform supports a growing portfolio of LA injectable candidates across multiple therapeutic areas, all leveraging the same core technology.
Octavarus® is Innovarus's flagship product — a 3-month depot formulation of Octreotide for the treatment of Acromegaly and Gastroenteropancreatic Neuroendocrine Tumours (GEP-NET), offering patients a significant reduction in injection frequency.
* Pipeline stages are indicative. All product candidates are subject to regulatory review and clinical development timelines.
Innovarus operates from the Open Access Lab Mereside at Alderley Park, one of Europe's premier life science campuses located in Cheshire, England. This world-class facility provides access to cutting-edge equipment and a collaborative scientific community.
The campus, formerly AstraZeneca's global R&D headquarters, now hosts over 200 life science companies and provides the ideal environment for pharmaceutical formulation development and innovation.
At Innovarus, we believe that building a successful pharmaceutical company and operating responsibly are not competing goals — they are inseparable. Our ESG commitments are embedded in everything we do, from the materials we use to the patients we serve.
Innovarus offers a compelling investment opportunity at the intersection of pharmaceutical innovation and rare disease medicine. We are seeking strategic partners who share our vision of transforming patient care through long-acting injectable technology.
ISFI technology has been validated in multiple approved products globally. Innovarus applies this proven platform to new therapeutic areas with significant unmet need.
The global long-acting injectable market is valued at over $30 billion and growing at 8% annually, driven by demand for improved patient compliance solutions.
Our founders have previously developed and commercialised long-acting injectable products, bringing a track record of execution to Innovarus.
We are building a portfolio of patents around our formulation innovations, creating durable competitive advantages and barriers to entry.
Our 505(b)(2) and hybrid application strategy leverages existing safety data for approved active ingredients, reducing development risk and timelines.
Each pipeline candidate represents a distinct value inflection point, providing investors with multiple opportunities for return across a diversified portfolio.
Contact our team to request an investor presentation, data room access, or to arrange a meeting with our founders.
Since our founding, Innovarus has made rapid progress in building a differentiated pharmaceutical company focused on long-acting injectable technology for rare and chronic diseases.
Scientific and administrative initiatives, including chemical operations and market research, commenced — leading to the development of the viable and scalable concept of Octavarus®.
Formally established in the UK under registration number 15878502 by three co-founders, each bringing expertise in scientific operations, marketing and distribution, and organisational management.
Significant progress on both scientific and business fronts, effectively de-risking the entity and positioning Innovarus to engage with potential investors to secure additional resources and accelerate development.
Company News
Innovarus has secured laboratory space at the Open Access Lab Mereside, Alderley Park — one of the UK's premier life-science campuses — marking a significant milestone in the company's growth.
Science & Technology
Our proprietary In-Situ Forming Implant (ISFI) technology has demonstrated sustained drug release profiles of between one and twelve months in preclinical models, supporting the advancement of our pipeline candidates.
Pipeline
Innovarus's flagship product Octavarus® (Octreotide 3-Month Depot) for the treatment of Acromegaly and GEP-NET has progressed into the formulation development phase, bringing the company closer to first-in-human studies.
Whether you are a potential investor, a clinical partner, a patient organisation, or a fellow scientist — we welcome your enquiry. Our team will respond within two business days.
